Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002318188 | SCV000851433 | likely pathogenic | Inborn genetic diseases | 2017-07-05 | criteria provided, single submitter | clinical testing | The p.I3351F variant (also known as c.10051A>T), located in coding exon 52 of the DYNC1H1 gene, results from an A to T substitution at nucleotide position 10051. The isoleucine at codon 3351 is replaced by phenylalanine, an amino acid with highly similar properties. This variant has been determined to be the result of a de novo mutation or germline mosaicism in one family with an isolated case of DYNC1H1-related neurological disorder. This alteration is located in the microtubule-binding stalk of dynein motor domain and is indicated to be structurally disruptive (Ambry internal data; Mocz G et al. Structure, 2001 Feb;9:93-103; Kon T et al. Nature, 2012 Mar;484:345-50; Schmidt H et al. Nature, 2015 Feb;518:435-8; Bhabha G et al. Cell, 2014 Nov;159:857-68). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |